| A | B |
|---|
| fasting glucose level = 126 mg/dl, or 200 mg/dl non-fasting | thresholds for diagnosis of DM2 |
| fasting glucose = 110-126, or 140-200 2-hr-postprandial | levels that identify impaired glucose tolerance |
| impaired insulin secretion, insulin resistance | physiologic defects that characterize DM2 |
| renal disease, retinopathic changes, peripheral sensory deficit | microvascular complications related to uncontrolled hyperglycemia |
| sulfonylurea | increases sensitivity of beta cells and stimulates insulin release |
| biguanide | enhances tissue responsiveness to insulin |
| ACE inhibitor | reduces proteinuria, slows progression of renal disease |
| Somogyi | rebound hyperglycemia after insulin-induced hypoglycemia |
| hemoglobin A1c | assesses overall glycemic control for preceding 2-3 months |
| weight reduction to ideal body weight | the most important non-pharmacologic therapy |
